With its increasingly diverse tasks and functions, the IRS is in need of change, writes the author. She explores the agency's performance during the COVID-19 pandemic and the challenges it faces in Law360.
Companies developing stem cell-based interventions should work with policymakers and patient advocates to address risks for current and future patients and to protect clinical research and the reputation of the field, write the authors. Read their full article in Cell & Gene Therapy Insights (free registration).
It now seems technically feasible to culture human embryos beyond the “fourteen‐day limit,” which has the potential to increase scientific understanding of human development and perhaps improve infertility treatments. Robust stakeholder engagement preceded adoption of the fourteen‐day limit and should arguably be part of efforts to reassess it, write the authors.
Kirstin R.W. Matthews, Ana S. Iltis, Daniel S. Wagner, Nuria Gallego Marquez, Jason Scott Robert, Inmaculada de Melo-Martín, Marieke Bigg, Sarah Franklin, Soren Holm, Ingrid Metzler, Matteo A. Molè, Jochen Taupitz, Giuseppe Testa, Jeremy SugarmanFebruary 26, 2021
Existing innovation in outcomes measurement and resource management, coupled with the competitive pressures of Covid-19, create a unique window for value creation within surgical care, the authors write. Read their article in the Annals of Surgery.
Anaeze C. Offodile II, Kushal T. Kadakia, Lee Fleisher, C.J. Stimson, Thomas AloiaJuly 26, 2020
This paper, published in the Virginia Tax Review, explores the mixed effects of technological advancements on tax compliance — and, thus, its counterpart, tax noncompliance.
The authors examine the Internal Revenue Service’s audit campaign strategy — in particular, the related-party transactions campaign — and what it means for mid-market taxpayers.